Market Overview

UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

Share:
Related IMGN
ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference
Buy ImmunoGen On Transformational Products, Jefferies Says
ImmunoGen to evaluate combo of lead product candidate and Merck's Keytruda in ovarian cancer (Seeking Alpha)

Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN) from Outperform to Perform and maintained a $14.00 price target.

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to IMGN901 and will watch the NORTH study as it will likely be the next driver of IMGN that could move us off the sidelines. A NORTH update is expected 2H13. With the launch of T-DM1, as with any drug launch, initial Street expectations may be adjusted. A post-launch pullback in IMGN into low teens may also cause us to revisit our rating."

ImmunoGen closed at $15.04 on Friday.

Latest Ratings for IMGN

DateFirmActionFromTo
Nov 2015JefferiesAssumesHoldBuy
Oct 2015Leerink SwannMaintainsMarket Perform
Sep 2015Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (IMGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters